Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

IRX-2, Cyclophosphamide, and Nivolumab in Treating Patients with Recurrent or Metastatic Solid Tumors

Trial Status: administratively complete

This phase Ib trial studies the best dose and side effects of IRX-2 in combination with cyclophosphamide and nivolumab in treating patients with solid tumors that have come back (recurrent) or have spread to other parts of the body (metastatic). IRX-2 is a cell derived biologics which is made by cells of the immune system (a system that defends the body against infections). IRX-2 regimen may attempt to correct immune system defect and restore the immune system in order to improve the body’s ability to fight the cancer. Cyclophosphamide may help in reversing suppression of immune response in cancer patients and reducing the immunosuppressive effects of T regulated cells. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving IRX-2 and cyclophosphamide with nivolumab may work better than nivolumab alone in treating patients with recurrent or metastatic solid tumors.